Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Pfizer
Age
11–14
Sex
ALL
Healthy volunteers
Accepted
You may be eligible if
Male or female participants 11 through \<15 years of age at the time of randomization.
Participants who have never received a prior dose of any meningococcal vaccine. Written confirmation of vaccination history must be obtained prior to randomization.
Available for the entire study period and can be reached by telephone.
Healthy participant as determined by medical history, physical examination, and judgement of the investigator.
Negative urine pregnancy test for all female participants; pregnancy test is not applicable to male participants.
You may not be if
A previous anaphylactic reaction to any vaccine or vaccine-related component.
Bleeding diathesis or condition associated with prolonged bleeding time that would contraindicate intramuscular injection.
A known or suspected defect of the immune system that would prevent an immune response to the vaccine, such as participants with congenital or acquired defects in B-cell function, those receiving chronic systemic (oral, intravenous, or intramuscular) corticosteroid therapy, or those receiving immunosuppressive therapy.
History of microbiologically proven disease caused by Neisseria meningitidis or Neisseria gonorrhoeae.
Significant neurological disorder or history of seizure (excluding simple febrile seizure).
Any neuroinflammatory or autoimmune condition, including, but no limited to, transverse myelitis, uveitis, optic neuritis, and multiple sclerosis.
Participants receiving any allergen immunotherapy with a nonlicensed product or receiving allergen immunotherapy with a licensed product and are not on stable maintenance doses.
Receipt of any blood products, including immunoglobulin, within 6 months before the first study vaccination.
Current use of systemic antibiotics with no foreseeable date of discontinuation prior to anticipated date of enrollment (first vaccination).
